Attorney Docket No: 25436/1510 (Serial No.:09/637,650)

Inventor: Chao-Feng Zheng Filed: August 11, 2000 Amendment and Reply

Page 2

Transmitted herewith is a copy of the "Sequence Listing" (sheets 1/3 through 3/3) in paper form for the above-identified patent application as required by 37 C.F.R. §1.821(c) and a copy of the Sequence Listing in computer readable form as required by 37 C.F.R. §1.821(e). As required by 37 C.F.R. §1.821(f), Applicant's Attorney hereby states that the content of the "Sequence Listing" in paper form and the computer readable form of the "Sequence Listing" are the same and, as required by 37 C.F.R. §1.821(g), also states that the submission includes no new matter.

Applicant's Attorney submits herewith amendments to comply with 37 C.F.R. §1.825. Please enter the following amendments and remarks.

AMENDMENTS

In the specification:

Please insert the attached "Sequence Listing" (sheets 1/3 through 3/3), and comprising SEQ ID NOs:1-10, into the above-referenced application.

Please replace the paragraph at page 15, lines 12 through 19, with the following paragraph:



As used herein, the term "sequence-specific DNA binding protein" refers to a protein that recognizes and binds a specific DNA sequence. The sequence bound by a sequence-specific DNA binding protein may be an invariant arrangement of contiguous nucleotide residues (e.g., GGATCC; SEQ ID NO:1) or it may be a conserved sequence motif in which individual residues may vary and still allow recognition and binding by the sequence-specific DNA binding protein (e.g., GGPuPyCC (SEQ ID NO:2), wherein Pu and Py are purine and pyrimidine, respectively). Binding of the protein to its specific sequence may be assessed via any conventional protein:nucleic acid binding methods, including but not limited to electrophoretic gel analysis of a given protein:nucleic acid construct.

Attorney Docket No: 25436/1510 (Serial No.:09/637,650)

Inventor: Chao-Feng Zheng Filed: August 11, 2000 Amendment and Reply

Page 3

Please replace the paragraph at page 20, lines 4 through 7, with the following paragraph:

Co

A schematic diagram of the pFR-Luc reporter vector is shown. Five copies of the GAL4 DNA-binding domain recognition sequence (underlined; SEQ ID NOs:3, 4, 5, 6, 7) are linked to a minimal promotor containing a TATA element upstream of the initiator ATG initiator codon of firefly luciferase coding sequences.

Please replace the paragraph at page 20, lines 10 through 14, with the following paragraph:

GD

A schematic diagram of the plasmid pFA-CMV, used as the base vector for the fusion transactivator plasmids according to the invention is shown. The vector fuses the GAL4 DNA-binding domain (amino acids 1-147) to the selected fusion transactivation domain via the shown multiple cloning site (SEQ ID NOs:8, 9). Expression of the resulting fusion transactivator protein is driven by the strong CMV promoter.

Please replace the paragraph at page 36, lines 1 through 7, with the following paragraph:

CH

To facilitate the integration and selection for stable reporter gene integration, a hygromycin resistance expression cassette, excised from p3'SS (a vector for LacSwitchTM expression systems (Stratagene), GenBank Accession No. U42371), was inserted into the Ndel site of the pFR-Luc (Genbank Accession No. AF058756) luciferase reporter vector, to generate pFR-Luc-Hyg. pFR-Luc (and therefore pFR-Luc-Hyg) carries five copies of the GAL4 DNA-binding domain recognition sequence 5'-CGGAGTACTGTCCTCCG-3' (SEQ ID NO:10) upstream of a basic TATA element and the coding region for firefly luciferase (see Figure 4).